WallStreetZenWallStreetZen

NASDAQ: VXRT
Vaxart Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for VXRT

Based on 2 analysts offering 12 month price targets for Vaxart Inc.
Min Forecast
$6.00+455.56%
Avg Forecast
$7.00+548.15%
Max Forecast
$8.00+640.74%

Should I buy or sell VXRT stock?

Based on 2 analysts offering ratings for Vaxart Inc.
Buy
Strong Buy
1 analysts 50%
Buy
0 analysts 0%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VXRT stock forecasts and price targets.

VXRT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Cantor Fitzgerald
Top 2%
99
Strong BuyMaintains$8.00+640.74%2022-09-02
B. Riley Securities
Top 1%
100
HoldMaintains$6.00+455.56%2022-05-19

1 of 1

Forecast return on equity

Is VXRT forecast to generate an efficient return?
Company
9.66%
Industry
15.35%
Market
62.84%
VXRT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VXRT forecast to generate an efficient return on assets?
Company
6.74%
Industry
13.55%
VXRT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VXRT earnings per share forecast

What is VXRT's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$0.84
Avg 2 year Forecast
-$0.93
Avg 3 year Forecast
-$0.49

VXRT revenue forecast

What is VXRT's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$233.0k+46.54%
Avg 2 year Forecast
$300.0k+88.68%
Avg 3 year Forecast
$84.1M+52,818.87%
VXRT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VXRT revenue growth forecast

How is VXRT forecast to perform vs Biotechnology companies and vs the US market?
Company
689.21%
Industry
24.83%
Market
6.69%
VXRT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VXRT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VXRT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VXRT$1.08$7.00+548.15%Buy
BIVI$4.65$8.00+72.04%Strong Buy
TCRT$0.67$3.00+350.45%Strong Buy
RVLP$1.46$3.50+139.73%Buy
CABA$5.00$8.00+60.00%Strong Buy

Vaxart Stock Forecast FAQ

Is Vaxart Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: VXRT) stock is to Buy VXRT stock.

Out of 2 analysts, 1 (50%) are recommending VXRT as a Strong Buy, 0 (0%) are recommending VXRT as a Buy, 1 (50%) are recommending VXRT as a Hold, 0 (0%) are recommending VXRT as a Sell, and 0 (0%) are recommending VXRT as a Strong Sell.

If you're new to stock investing, here's how to buy Vaxart stock.

What is VXRT's earnings growth forecast for 2022-2024?

(NASDAQ: VXRT) Vaxart's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 7.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.02%.

Vaxart's earnings in 2022 is -$104,604,000.On average, 4 Wall Street analysts forecast VXRT's earnings for 2022 to be -$110,249,232, with the lowest VXRT earnings forecast at -$127,311,613, and the highest VXRT earnings forecast at -$82,686,924. On average, 4 Wall Street analysts forecast VXRT's earnings for 2023 to be -$122,061,650, with the lowest VXRT earnings forecast at -$173,248,794, and the highest VXRT earnings forecast at -$77,436,961.

In 2024, VXRT is forecast to generate -$64,312,052 in earnings, with the lowest earnings forecast at -$162,748,867 and the highest earnings forecast at $64,312,052.

What is VXRT's revenue growth forecast for 2022-2024?

(NASDAQ: VXRT) Vaxart's forecast annual revenue growth rate of 689.21% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 24.83%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 6.69%.

Vaxart's revenue in 2022 is $159,000.On average, 3 Wall Street analysts forecast VXRT's revenue for 2022 to be $30,581,037, with the lowest VXRT revenue forecast at $13,124,909, and the highest VXRT revenue forecast at $39,374,726. On average, 1 Wall Street analysts forecast VXRT's revenue for 2023 to be $39,374,726, with the lowest VXRT revenue forecast at $39,374,726, and the highest VXRT revenue forecast at $39,374,726.

In 2024, VXRT is forecast to generate $11,043,429,345 in revenue, with the lowest revenue forecast at $1,916,236,656 and the highest revenue forecast at $28,956,829,599.

What is VXRT's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: VXRT) forecast ROA is 6.74%, which is lower than the forecast US Biotechnology industry average of 13.55%.

What is VXRT's Price Target?

According to 2 Wall Street analysts that have issued a 1 year VXRT price target, the average VXRT price target is $7.00, with the highest VXRT stock price forecast at $8.00 and the lowest VXRT stock price forecast at $6.00.

On average, Wall Street analysts predict that Vaxart's share price could reach $7.00 by Sep 2, 2023. The average Vaxart stock price prediction forecasts a potential upside of 548.15% from the current VXRT share price of $1.08.

What is VXRT's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: VXRT) Vaxart's current Earnings Per Share (EPS) is -$0.83. On average, analysts forecast that VXRT's EPS will be -$0.84 for 2022, with the lowest EPS forecast at -$0.97, and the highest EPS forecast at -$0.63. On average, analysts forecast that VXRT's EPS will be -$0.93 for 2023, with the lowest EPS forecast at -$1.32, and the highest EPS forecast at -$0.59. In 2024, VXRT's EPS is forecast to hit -$0.49 (min: -$1.24, max: $0.49).

What is VXRT's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: VXRT) forecast ROE is 9.66%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.